Acute Kidney InjuryPRESSINGNCT06714214
PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin
An observational study of Acute Kidney Injury, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 3 sites in Italy.
Trial summary
The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury
- How many people
- 152 participants
- Where
- 3 sitesItaly
- Study dates
- 1 Oct 2024to Nov 2028
- How long will I take part?
- 28 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will include all adult patients suffering from acute renal injury needing to CRRT, admitted to the enrolling centers starting from the approval of the Ethics Committee
Who may be able to join
- age ≥ 18 years;
- diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria)
- need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice
- Obtaining informed consent
Who cannot join
- CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care;
- diagnosis of ESRF on admission;
- Discontinuation of CRRT under conditions that do not comply with the criteria established by the study;
- Need for CRRT not associated with AKI condition (e.g. elimination of toxicants);
- pregnant women;
- patient with known neoplastic disease.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Italy3 sites, 3 recruiting
- Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Anestesia polispecialistica e rianimazione
Bologna, Bologna, 40138
Francesco Marino, MD, +39 3293842166, francesco.marino@aosp.bo.it
Francesco Marino
- Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna -Anestesiologia e terapia intensiva polivalente
Bologna, Bologna, 40138
Elisabetta Pierucci, MD, 0512144309, elisabetta.pierucci@aosp.bo.it
Elisabetta Pierucci, MD
- Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna -Anestesia e terapia intensiva cardiovascolare
Bologna, Bo, 40138
Fabrizio Monaco, MD, 0512144309, fabrizio.monaco4@unibo.it
Fabrizio Monaco, MD
About this study
The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support
- Conditions
- Acute Kidney Injury
- Keywords
- C cistatin, acute kidney injury, CRRT, weaning
- Medical subject headings
- Acute Kidney Injury
What is being measured
The primary outcome is the main question the study is designed to answer.
the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU
To verify whether the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU It is measured as (cistatin at weaning minus cistatin basal) divided by cistatine basal, in percentage
Measured: From enrlollment to the weaning from CRRT and 14 days after
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2024
- Study start1 Oct 2024
- Primary completionAug 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by IRCCS Azienda Ospedaliero-Universitaria di BolognaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 152 participants (estimated)
- Target duration
- 28 Days
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Francesco Marino, MD, Principal investigator, IRCCS Azienda Ospedaliero-Universitaria di Bologna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06714214
- Sponsor's protocol ID
- PRESSING
- Acronym
- PRESSING
- Status last verified
- Nov 2026
- First submitted
- 28 Nov 2024
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin
- ClinicalTrials.gov ID
- NCT06714214
- Acronym / sponsor ID
- PRESSING / PRESSING
- Conditions
- Acute Kidney Injury
- Keywords
- C cistatin, acute kidney injury, CRRT, weaning
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 152 participants (estimated)
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- Aug 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 3 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 28 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include all adult patients suffering from acute renal injury needing to CRRT, admitted to the enrolling centers starting from the approval of the Ethics Committee
Key inclusion criteria (4 listed)
- age ≥ 18 years;
- diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria)
- need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice
- Obtaining informed consent
Key exclusion criteria (6 listed)
- CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care;
- diagnosis of ESRF on admission;
- Discontinuation of CRRT under conditions that do not comply with the criteria established by the study;
- Need for CRRT not associated with AKI condition (e.g. elimination of toxicants);
- pregnant women;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU
Time frame: From enrlollment to the weaning from CRRT and 14 days after
To verify whether the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU It is measured as (cistatin at weaning minus cistatin basal) divided by cistatine basal, in percentage
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Francesco Marino, MD principal investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 3 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Francesco Marino, MD (3293842166, francesco.marino@aosp.bo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU (time frame: From enrlollment to the weaning from CRRT and 14 days after). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.